Wockhardt sells animal health biz

Pharmaceutical major Wockhardt, which is trying to repay its debts of over Rs 3,400 crore, today announced it had signed an agreement to divest its animal health division to Vétoquinol, a French veterinary care company.

Sources said the deal was worth Rs 170 crore. Wockhardt’s animal health business had net sales of Rs 77 crore for the year ended December 31, 2008.

The deal is subject to necessary administrative approvals and should take effect in the second half of 2009, said the press release.

Vétoquinol, a family-owned group specialising exclusively in animal health, is the 11th largest animal health company in the world. Nearly 80 per cent of Vétoquinol’s revenues come from outside France, said the release. had already got shareholder approval to sell its animal healthcare division. French veterinary major Virbac, multinational Sanofi-Aventis and Pfizer were interested, sources said. Pfizer has acquired Vetnex, the animal health business of RFCL Ltd from ICICI Venture.

Wockhardt, which is currently trying to restructure its loans through a corporate debt restructuring, had sold its German subsidiary Esparma to Mova GmbH, a subsidiary of German company Lindopharm GmbH, for Rs 120 crore.

The company has to repay foreign currency convertible bonds worth over Rs 600 crore by October and has pledged various assets to meet liabilities.

High-value acquisitions in the past and losses from foreign currency transactions caused huge losses for the company. The company posted Rs 159 crore loss on sales of Rs 3,592 crore.

Chairman Habil Khorakiwala-promoted Hospitals is also trying to rope in a strategic investor, either by sale of minority stake in the hospital chain or of two or three standalone hospitals in Mumbai, Bangalore and Kolkata, with plans to raise about Rs 750-900 crore.

Wockhardt’s other overseas assets, such as Morton Grove of the US and French subsidiary Negma Laboratories are also on the block, sources said.

The company is planning to hive off the biotech assets to a separate business and may rope in a strategic investor, they said.

image
Business Standard
177 22
Business Standard

Wockhardt sells animal health biz

BS Reporter  |  Mumbai 

Habil Khorakiwala

Pharmaceutical major Wockhardt, which is trying to repay its debts of over Rs 3,400 crore, today announced it had signed an agreement to divest its animal health division to Vétoquinol, a French veterinary care company.

Sources said the deal was worth Rs 170 crore. Wockhardt’s animal health business had net sales of Rs 77 crore for the year ended December 31, 2008.

The deal is subject to necessary administrative approvals and should take effect in the second half of 2009, said the press release.

Vétoquinol, a family-owned group specialising exclusively in animal health, is the 11th largest animal health company in the world. Nearly 80 per cent of Vétoquinol’s revenues come from outside France, said the release. had already got shareholder approval to sell its animal healthcare division. French veterinary major Virbac, multinational Sanofi-Aventis and Pfizer were interested, sources said. Pfizer has acquired Vetnex, the animal health business of RFCL Ltd from ICICI Venture.

Wockhardt, which is currently trying to restructure its loans through a corporate debt restructuring, had sold its German subsidiary Esparma to Mova GmbH, a subsidiary of German company Lindopharm GmbH, for Rs 120 crore.

The company has to repay foreign currency convertible bonds worth over Rs 600 crore by October and has pledged various assets to meet liabilities.

High-value acquisitions in the past and losses from foreign currency transactions caused huge losses for the company. The company posted Rs 159 crore loss on sales of Rs 3,592 crore.

Chairman Habil Khorakiwala-promoted Hospitals is also trying to rope in a strategic investor, either by sale of minority stake in the hospital chain or of two or three standalone hospitals in Mumbai, Bangalore and Kolkata, with plans to raise about Rs 750-900 crore.

Wockhardt’s other overseas assets, such as Morton Grove of the US and French subsidiary Negma Laboratories are also on the block, sources said.

The company is planning to hive off the biotech assets to a separate business and may rope in a strategic investor, they said.

RECOMMENDED FOR YOU

Wockhardt sells animal health biz

Pharmaceutical major Wockhardt, which is trying to repay its debts of over Rs 3,400 crore, today announced it had signed an agreement to divest its animal health division to Vétoquinol, a French veterinary care company.

Pharmaceutical major Wockhardt, which is trying to repay its debts of over Rs 3,400 crore, today announced it had signed an agreement to divest its animal health division to Vétoquinol, a French veterinary care company.

Sources said the deal was worth Rs 170 crore. Wockhardt’s animal health business had net sales of Rs 77 crore for the year ended December 31, 2008.

The deal is subject to necessary administrative approvals and should take effect in the second half of 2009, said the press release.

Vétoquinol, a family-owned group specialising exclusively in animal health, is the 11th largest animal health company in the world. Nearly 80 per cent of Vétoquinol’s revenues come from outside France, said the release. had already got shareholder approval to sell its animal healthcare division. French veterinary major Virbac, multinational Sanofi-Aventis and Pfizer were interested, sources said. Pfizer has acquired Vetnex, the animal health business of RFCL Ltd from ICICI Venture.

Wockhardt, which is currently trying to restructure its loans through a corporate debt restructuring, had sold its German subsidiary Esparma to Mova GmbH, a subsidiary of German company Lindopharm GmbH, for Rs 120 crore.

The company has to repay foreign currency convertible bonds worth over Rs 600 crore by October and has pledged various assets to meet liabilities.

High-value acquisitions in the past and losses from foreign currency transactions caused huge losses for the company. The company posted Rs 159 crore loss on sales of Rs 3,592 crore.

Chairman Habil Khorakiwala-promoted Hospitals is also trying to rope in a strategic investor, either by sale of minority stake in the hospital chain or of two or three standalone hospitals in Mumbai, Bangalore and Kolkata, with plans to raise about Rs 750-900 crore.

Wockhardt’s other overseas assets, such as Morton Grove of the US and French subsidiary Negma Laboratories are also on the block, sources said.

The company is planning to hive off the biotech assets to a separate business and may rope in a strategic investor, they said.

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard